Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Cancer. 2011 Mar 28;117(19):4375–4380. doi: 10.1002/cncr.26078

Figure 2.

Figure 2

Sensitivity of breast cancer cells to TRAIL and doxorubicin. Cells of homozygous His64 genotype (open bars), heterozygous (hashed bars) or homozygous Pro64 (solid bars) were treated 4h with 100 ng/ml TRAIL (A) or overnight with 5 ug/ml doxorubicin (B) and cell viability was determined with the MTT assay.